Abstracts Archive - Page 2519 of 2607 - ACR Meeting Abstracts

Abstract Number: 1259 • 2012 ACR/ARHP Annual Meeting
Association Between Subclinical Atherosclerosis and Bone Mineral Density in Rheumatoid Arthritis
Barry J. Sheane¹, Ruth Dunne², Ken Scott³, Mary Hall⁴, Michelle O'Connor², Martin Healy⁵, John Feely⁴, J.B. Walsh⁶ and Gaye Cunnane⁷, ¹Rheumatology, St. James Hospital, Dublin, Ireland, ²Diagnostic Imaging Department, St James's Hospital, Dublin 8, Ireland, ³Department of Pharmacology and Therapeutics, Trinity College Dublin, Dublin 8, Ireland, ⁴Department of Pharmacology and Therapeutics, St James's Hospital, Dublin 8, Ireland, ⁵Central Pathology Laboratory, Dublin 8, Ireland, ⁶Medicine for the Elderly, Dublin 8, Ireland, ⁷Dept of Rheumatology, St James's Hospital, Dublin, Ireland
Background/Purpose: Rheumatoid arthritis (RA) is associated with a higher risk of osteoporosis (OP) and cardiovascular disease (CVD). This cross-sectional study was undertaken to identify links…
Abstract Number: 1260 • 2012 ACR/ARHP Annual Meeting
Hydroxychloroquine Reduces the Risk of Coronary Artery Disease in Patients with Rheumatoid Arthritis
Li Chun¹, Mu Rong¹, Su Yin¹, Li Xiaofeng², Wang Yongfu³, Wang Guochun⁴, Zhu Ping⁵, Liu Xiangyuan⁶, Chen Haiying⁷, Cui Liufu⁸, Zhang Zhuoli⁹, Li Zhenbin¹⁰, Li Junfang¹¹, Zhang Fengxiao¹², Han Shuling¹³, Lin Jinying¹⁴, Liu Xiaomin¹⁵, Hu Shaoxian¹⁶, Yang Xiuyan¹⁷, Huang Cibo Sr.¹⁸, Li Xingfu¹⁹, Wang Yi²⁰ and Li Zhanguo¹, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ²Department of Rheumatology and Immunology, Taiyuan, China, ³Department of Rheumatology and Immunology, Baotou, China, ⁴Department of Rheumatology and Immunology, Beijing, China, ⁵Department of Rheumatology and Immunology,Xijing Hospital, Xian, China, ⁶Department of Rheumatology and Immunology,Peking University Third Hospital, Beijing, China, ⁷Department of Rheumatology and Immunology,The Third Hospital of, Shijiazhuang, China, ⁸Department of Rheumatology and Immunology,Kailuan hospital of North China Coal Hospital, Tangshan, China, ⁹Department of Rheumatology and Immunology,Peking University First Hospital, Beijing, China, ¹⁰Department of Rheumatology and Immunology,Peace Hospital, Shijiazhuang, China, ¹¹Department of Rheumatology and Immunology, Hebei Handan Central Hospital, Handan, China, ¹²Department of Rheumatology and Immunology,Hebei People's Hospital, China, ¹³Department of Rheumatology and Immunology, Peking University Shougang Hospital, Beijing, China, ¹⁴Department of Rheumatology and Immunology,The people's hospital of guangxi zhuang autonomous region, Nanning, China, ¹⁵Department of Rheumatology and Immunology,Beijing shunyi hospital of China Medical University, Beijing, China, ¹⁶Department of Rheumatology and Immunology,Tongji Medical College Huazhong University of Science & Technology, Wuhan, China, ¹⁷Department of Rheumatology and Immunology,First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, ¹⁸Rheumatology and Immunology Department, Beijing Hospital, Ministry of Health, Beijing, China, ¹⁹.Department of Rheumatology and Immunology,Qilu Hospital of Shandong University, Jinan, China, ²⁰Department of Rheumatology and Immunology,Second hospital of Lanzhou University, Lanzhou, China
Background/Purpose: Disease modifying anti-rheumatic drugs (DMARDs) can alter cardiovascular risk in RA by inflammation or by influencing cardiovascular risk factors indirectly. However, previous studies predominantly…
Abstract Number: 1261 • 2012 ACR/ARHP Annual Meeting
Epicardial Adipose Tissue Is Associated with Cardiometabolic Risk and the Metabolic Syndrome in Patients with Rheumatoid Arthritis
Michelle J. Ormseth¹, Aliza Lipson², Nikolaos Alexopoulos³, Gregory R. Hartlage³, Annette M. Oeser⁴, Aihua Bian⁴, Tebeb Gebretsadik⁵, Ayumi Shintani⁴, Paolo Raggi⁶ and C. Michael Stein⁷, ¹Rheumatology, Vanderbilt Medical Center, Nashville, TN, ²Rheumatology, Emory University, Atlanta, GA, ³Emory University, Atlanta, GA, ⁴Vanderbilt Medical Center, Nashville, TN, ⁵Biostatistics, Vanderbilt University, Nashville, TN, ⁶University of Alberta, Edmonton, AB, Canada, ⁷School of Medicine, Division of Clinical Pharmacology, Vanderbilt Medical Center, Nashville, TN
Background/Purpose: Patients with rheumatoid arthritis (RA) have increased coronary atherosclerosis and this may be related to their increased prevalence of visceral adiposity, insulin resistance, and…
Abstract Number: 1262 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients with Higher Disease Severity and Subclinical Carotid Plaque Experience More Cardiovascular Events Despite a Favorable Conventional Cadiovascular Risk Profiles
Yeon-Ah Lee¹, Somi Kim¹, Sang-Hoon Lee², Ran Song², Hyung In Yang² and Seung-Jae Hong¹, ¹Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, ²Rheumatology, Hospital at GANGDONG, Kyung Hee University, Seoul, South Korea
Background/Purpose: It has been shown that patients with rheumatoid arthritis (RA) experience cardiovascular (CV) events more often than expected. Increased risks of CV diseases in…
Abstract Number: 1263 • 2012 ACR/ARHP Annual Meeting
Carotid Arterial Wall Inflammation Is Associated with a Specific Profile of Inflammatory Biomarkers and Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis Patients
Caroline Grönwall¹, Gregg J. Silverman¹, Zahi Fayad², Venkatesh Mani², Victoria Furer³, Michael Farkouh², Manish Jain¹, Cheongeun Oh⁴, John Todd⁵, Mukundan Attur⁶, Steven B. Abramson⁷ and Jeffrey D. Greenberg⁸, ¹Rheumatology, NYU School of Medicine, New York, NY, ²Mount Sinai Hospital, New York, NY, ³Rheumatology, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ⁴Biostatistics, NYU School of Medicine, New York, NY, ⁵Singulex, Alameda, California, Alameda, CA, ⁶Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, ⁷Dept of Rheumatology/Medicine, NYU Langone Medical Center, New York, NY, ⁸New York Hospital for Joint Disease, New York, NY
Background/Purpose: Patients with RA are at increased risk of cardiovascular (CV) comorbidity and premature mortality. While generally attributed to accelerated atherosclerosis, the pathogenesis remains poorly understood.…
Abstract Number: 1264 • 2012 ACR/ARHP Annual Meeting
Vascular Age in Rheumatoid Arthritis Patients
Jl Rosales-Alexander¹, César Magro Checa¹, Juan Salvatierra¹, Silvia Montes García¹, Jesús Cantero Hinojosa² and Enrique Raya Álvarez¹, ¹Rheumatology, University Hospital San Cecilio, Granada, Spain, ²Internal Medicine, University Hospital San Cecilio, Granada, Spain
Background/Purpose: The European League Against Rheumatism (EULAR) recommends cardiovascular risk (CV) assessment using the systematic coronary risk evaluation (SCORE) chart in rheumatoid arthritis (RA) patients.…
Abstract Number: 1265 • 2012 ACR/ARHP Annual Meeting
Lipoprotein Subclass Particles and Small Vessel Elasticity As a Potential Marker for Early Atherosclerosis in Rheumatoid Arthritis: a Prospective, Controlled Study
Marty T. Mertens¹ and Elie Gertner², ¹Rheumatology, University of Minnesota, Minneapolis, MN, ²Section of Rheumatology, Regions Hospital and University of Minnesota Medical School, St. Paul, MN
Background/Purpose: Rheumatoid arthritis (RA) has increased rates of cardiovascular (CV) events. However, standard CV risk factors, such as routine lipid profiles, are not different in…
Abstract Number: 1266 • 2012 ACR/ARHP Annual Meeting
Evaluation of Metabolic Syndrome in 97 Patients with Rheumatoid Arthritis
Fernanda G. G Chaer¹, Juliana Lucena², Rogerio Castro Reis³, Fabiola Brasil², Murilo Melo⁴, Amanda Callegari⁵ and Branca Souza⁵, ¹Reumatologia, Santa Casa de Sao Paulo, São Paulo, Brazil, ²Reumatologia, Irmandade da Santa Casa de Misericordia de Sao Paulo, São Paulo, Brazil, ³Reumatologia, Santa Casa de Sao Paulo, São Paulo, Brazil, ⁴Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, ⁵Reumatologia, Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil
Background/Purpose: Rheumatoid arthritis (RA) is an independent risk factor for cardiovascular disease (CVD), which is the leading cause of death in this group. Thus, the…
Abstract Number: 1267 • 2012 ACR/ARHP Annual Meeting
Inflammatory Burden Predicts Progression of Carotid Plaque in Rheumatoid Arthritis: A 24-Month Longitudinal Analysis
Churl Hyun Im¹, Na Ri Kim¹, Jong Wan Kang¹, Young Ji Kim¹, Kyung Hye Kim¹, Eon Jeong Nam¹ and Young Mo Kang², ¹Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea, ²Department of Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea
Background/Purpose: Carotid atherosclerosis, which is associated with the increased risk of cardiovascular (CV) disease, is increased in rheumatoid arthritis (RA) patients. In our previous study,…
Abstract Number: 1268 • 2012 ACR/ARHP Annual Meeting
Lipid Alterations and Measurement of Arterial Stiffness in Rheumatoid Arthritis
Marina Scolnik¹, Carla Saucedo², David A. Navarta³, Leandro Ferreyra Garrott², Erika Catay⁴, Maria L. Acosta Felquer⁵, Eliana Lancioni⁶, Cristian Quiroz³, Federica Varela Guidetti⁵, Zaida Bedran², Mirtha Sabelli⁴, Javier Rosa⁴, Maria Victoria Garcia⁴, Patricia M. Imamura⁵, Patricia Sorroche⁷, Jose Alfie⁸, Margarita Morales⁹, Gabriel Waisman⁹, Luis J. Catoggio¹ and Enrique Soriano¹, ¹Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Internal Medicine, Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Internal Medicine, Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁶Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁷Central Laboratory , Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁸Internal Medicine, Hypertension Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁹Hypertension Section, Internal Medicine Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease. Increased arterial stiffness, an independent risk factor for premature coronary artery disease, has been reported in…
Abstract Number: 1269 • 2012 ACR/ARHP Annual Meeting
Serum Cytokines Associated with Carotid Atherosclerosis in Rheumatoid Arthritis
Inmaculada del Rincon¹, Roy W. Haas², Daniel H. O'Leary³, Joseph F. Polak³, Daniel F. Battafarano⁴ and Agustin Escalante⁵, ¹Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Dept. of Medicine-Rheumatology, University of Texas Health Science Center, San Antonio, TX, ³Radiology, Tufts University-Boston Campus, Boston, MA, ⁴Medicine / MCHE-MDR, Brooke Army Medical Ctr, San Antonio, TX, ⁵Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: The mechanism for the increased cardiovascular morbidity and mortality in rheumatoid arthritis (RA) is incompletely understood. In a previous analysis, we found that both…
Abstract Number: 1270 • 2012 ACR/ARHP Annual Meeting
Role of Inflammation, Serologic Status and Low Density Lipoprotein in Coronary Heart Disease Among Patients with Rheumatoid Arthritis: Data From the National Veterans Health Administration
Iris Navarro-Millan¹, Shuo Yang², Scott L. DuVall³, Lang Chen⁴, John Baddley⁵, Grant W. Cannon⁶, Elizabeth S. Delzell⁷, Jie Zhang⁸, Monika M. Safford⁹, Nivedita M. Patkar¹⁰, Ted R. Mikuls¹¹, Jasvinder A. Singh¹² and Jeffrey R. Curtis⁸, ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁶Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁷Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁸Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁹Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹⁰Immunology/Rheumatology, Univ of Alabama-Birmingham, Birmingham, AL, ¹¹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ¹²Department of Medicine, University of Alabama, Tuscaloosa, AL
Background/Purpose: Rheumatoid arthritis (RA) increases the risk for coronary heart disease and ischemic events like myocardial infarction (MI). The association between traditional cardiovascular risk factors in…
Abstract Number: 1271 • 2012 ACR/ARHP Annual Meeting
Two-Year Drug Survival and Treatment Effect of Abatacept and Tocilizumab in the Treatment of Rheumatoid Arthritis in Routine Care. Results From the Nationwide Danish Danbio Registry
HC Leffers¹, Mikkel Østergaard¹, Bente Glintborg², Niels Steen Krogh³, Ulrik Tarp⁴, Tove Lorenzen⁵, Annette Hansen⁶, Michael Sejer Hansen⁷, Lene Dreyer², Martin S. Jakobsen² and Merete Lund Hetland⁸, ¹DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Glostrup, Denmark, ²DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, ³ZiteLab ApS, Copenhagen, Denmark, ⁴Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁵Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, ⁶Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, ⁷Gildhøj Privathospital, Copenhagen, Denmark, ⁸DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark
Background/Purpose: Abatacept and tocilizumab have been shown to be efficacious for the treatment of rheumatoid arthritis (RA), even in patients refractory to tumor necrosis factor…
Abstract Number: 1272 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA) Incomplete Secondary Responders to TNF-Alpha Safely Achieve Efficacy by Switching to Certolizumab Pegol in a 24-Week Study: A Phase IV, Randomized Multicenter, Double-Blind, Twelve-Week Study Followed by a 12 -Week Open-Label Phase
M. Schiff¹, Ronald Goldblum² and John RP Tesser³, ¹University of Colorado, Denver, CO, ²CPC, Inc, Carlsbad, CA, ³AZ Arthritis Rheum Assoc, Paradise Valley, AZ
Background/Purpose: Certolizumab pegol (CZP), an inhibitor of TNF-alpha, has demonstrated rapid and sustained efficacy in RA patients. Switching from one anti-TNF therapy to another has…
Abstract Number: 1273 • 2012 ACR/ARHP Annual Meeting
Can Response Duration After the First Rituximab Treatment Be Used in Timing of Rituximab Retreatment?
Noortje van Herwaarden¹, Aatke van der Maas¹, Tim L. Jansen², Ellen Dutmer³, Andre Hartkamp⁴, Piet L.C.M. van Riel⁵, Wietske Kievit⁵, Bart J.F. van den Bemt⁶ and Alfons A. den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Rheumatology, Radboud UMC, Nijmegen, Netherlands, ³Rheumatology, Gelderse Vallei Hospital, Ede, Netherlands, ⁴Reumatology, Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands, ⁵Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁶Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: The optimal retreatment strategy for rituximab is not clear1. Different strategies are being used in clinical practice, including: on demand retreatment when disease activity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].